Stockscreener 앱 받기
2.20
5.77%
0.12
전일 마감가:
$2.08
열려 있는:
$2.08
하루 거래량:
1.90M
Relative Volume:
0.61
시가총액:
$211.78M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.3253
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
+4.76%
1개월 성능:
-7.95%
6개월 성능:
+30.18%
1년 성능:
-9.47%
1일 변동 폭
$2.0401
$2.245
1주일 범위
$2.0401
$2.25
52주 변동 폭
$0.9857
$3.67
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.20 | 200.23M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 재개 | Jefferies | Buy |
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-02-05 | 개시 | Jefferies | Buy |
| 2023-11-29 | 개시 | William Blair | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | Stifel | Buy |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Guidance Update: Is Cabaletta Bio Incs ROIC above industry averageJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Portfolio Recap: Can Cabaletta Bio Inc disrupt its industryOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Is Cabaletta Bio Incs ROIC above industry averageMarket Growth Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Cabaletta Bio stock rating reiterated by Cantor Fitzgerald on IND clearance By Investing.com - Investing.com South Africa
Cabaletta Bio stock rating reiterated by Cantor Fitzgerald on IND clearance - Investing.com
CABA Initiates Key Trials and Advances Manufacturing for Rese-Ce - GuruFocus
Cabaletta Bio Announces 2026 Strategic Priorities - The Manila Times
Cabaletta Bio, Inc. Announces 2026 Strategic Priorities - TradingView — Track All Markets
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms - Caledonian Record
Technical Analysis: Can Cabaletta Bio Inc stock deliver surprise earnings beatJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - Bộ Nội Vụ
Gains Recap: Can Cabaletta Bio Inc. stock hit analyst price targets2025 Volatility Report & Verified Short-Term Plans - Улправда
Is Cabaletta Bio Inc. stock a top momentum playJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
Aug Intraday: How sustainable is Cabaletta Bio Inc. stock dividend payoutTrade Volume Report & Weekly Breakout Stock Alerts - Улправда
Is Cabaletta Bio Inc a good long term investmentPrice Volatility Patterns & Free High Profit Capital Plays - earlytimes.in
Cabaletta Bio slides on proposed securities offering - MSN
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Smart Money: Is Cabaletta Bio Inc stock a top momentum playMarket Trend Summary & Technical Buy Zone Confirmations - moha.gov.vn
Cabaletta Bio Inc. (CABA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cabaletta Bio Inc. stock gaining market shareLong-Term Investment Plans & Small Budget Capital Growth - Bollywood Helpline
Unraveling Cabaletta Bio Inc.’s Recent Market Moves - StocksToTrade
Bull Bear: Will CHEF stock reach Wall Street targetsWeekly Stock Report & Daily Market Momentum Tracking - moha.gov.vn
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to NASDAQ Biotechnology Index - marketscreener.com
History Review: Is Cabaletta Bio Inc. stock gaining market shareMarket Volume Summary & Daily Technical Forecast Reports - Улправда
Update Report: Is Cabaletta Bio Inc. stock gaining market shareProfit Target & Stepwise Trade Signal Guides - ulpravda.ru
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - ulpravda.ru
Sentiment Watch: Will Cabaletta Bio Inc. stock recover faster than marketChart Signals & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cabaletta Bio Inc. stock continue upward momentumMarket Rally & Capital Efficiency Focused Ideas - Улправда
Will Cabaletta Bio Inc. stock split again soonQuarterly Investment Review & AI Based Buy and Sell Signals - DonanımHaber
Can Cabaletta Bio Inc. stock deliver surprise earnings beatMarket Sentiment Review & Entry and Exit Point Strategies - DonanımHaber
How Cabaletta Bio Inc. stock benefits from global expansionCPI Data & Expert Curated Trade Setups - bolumsonucanavari.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - MSN
Profit Review: Will Cabaletta Bio Inc. stock recover faster than marketRisk Management & Long Hold Capital Preservation Plans - Улправда
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Yahoo Finance
Cabaletta Bio (CABA) price target increased by 15.31% to 14.41 - MSN
Cabaletta Bio, Inc. $CABA Shares Acquired by Bain Capital Life Sciences Investors LLC - MarketBeat
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment - MSN
CABA Receives FDA Orphan Status for Myasthenia Gravis Treatment - GuruFocus
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Weekly Earnings: Will Cabaletta Bio Inc stock recover faster than marketMarket Sentiment Report & Technical Pattern Based Buy Signals - moha.gov.vn
Cabaletta Bio (CABA) Price Target Increased by 15.31% to 14.41 - Nasdaq
Cabaletta Bio (CABA) Stock Analysis Report | Financials & Insights - Benzinga
Evercore Healthcare Conference - marketscreener.com
Is Cabaletta Bio Inc stock gaining market shareWeekly Trading Summary & Low Risk High Win Rate Picks - BỘ NỘI VỤ
6 Companies Hanging On in Cell Therapy - BioSpace
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Form 8-KCurrent report - ADVFN
Jefferies Financial Group Inc. Takes $3.04 Million Position in Cabaletta Bio, Inc. $CABA - MarketBeat
Cabaletta Bio to Present at Key Global Healthcare and Immunology Conferences - MSN
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):